5-ALA Composition for Suppressing Sickle Cell Polymerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for sickle cell disease (SCD) are not consistently effective and can have significant side effects, necessitating the development of more effective treatments to ameliorate and prevent the symptoms associated with SCD.
Innovation Solution
The use of 5-aminolevulinic acid (5-ALA) or its derivatives, potentially combined with metal-comprising compounds, to suppress the increase in sickle cells, particularly in hypoxic conditions, thereby preventing or ameliorating SCD symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to enhance HbF expression and suppress HbS polymerization, then the efficacy is not constant for each cell or patient, but careful follow-up is required during use
Solution Approach 1:
The patent changes the biochemical parameter target from HbF expression enhancement to direct suppression of HbS polymerization and sickle cell formation. 5-ALA acts by inhibiting the polymerization process itself rather than indirectly through HbF upregulation, providing more consistent and predictable therapeutic effects across different patients without requiring intensive monitoring for variable responses
2Reliability
If HDAC inhibitors are used to suppress HbS polymerization, then the drug efficacy is improved, but intermittent administration is required to avoid toxicity
Solution Approach 1:
The patent shifts from epigenetic modification via HDAC inhibition to direct biochemical intervention in the HbS polymerization pathway. 5-ALA and its derivatives act by directly interfering with the polymerization process at the molecular level, achieving therapeutic efficacy without the cumulative toxicity associated with intermittent HDAC inhibitor administration
Solution Approach 2:
The patent introduces 5-ALA and its derivatives as intermediary compounds that specifically target the HbS polymerization process. These compounds act as molecular mediators that bind to or interfere with the polymerization interface of HbS molecules, providing a more selective and less toxic mechanism compared to broad-spectrum HDAC inhibitors
3Reliability
If carbon monoxide drugs are used to suppress sickling by suppressing deoxygenation of HbS, then the sickling is suppressed, but side effects on organs having high oxygen demand occur
Solution Approach 1:
The patent converts the harmful effect of oxygen deprivation (which causes sickling) into a therapeutic opportunity by using 5-ALA to directly suppress polymerization. Instead of trying to prevent deoxygenation systemically (which harms oxygen-demanding organs), the invention allows normal oxygen transport while blocking the pathological polymerization that occurs during deoxygenation, thus eliminating sickling without compromising organ oxygen supply
4Reliability
If N-acetylcysteine is used to suppress ischemia reperfusion and ROS production, then the protective effect is achieved, but the application has not yet been approved as a therapeutic agent for SCD
Solution Approach 1:
The patent shifts from antioxidant therapy (ROS suppression) to direct anti-polymerization therapy. 5-ALA and its derivatives target the fundamental pathological process of HbS polymerization rather than secondary oxidative stress, providing a more direct and mechanism-based treatment that addresses the root cause of sickling and has progressed to regulatory approval
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
5-ALA significantly reduces the number of sickle cells and alleviates hypoxia-induced acute symptoms, improving the quality of life for SCD patients with minimal side effects.
Implementation Method 1
5-ALA suppresses an increase in sickle cells in SCD, and particularly significantly suppresses an increase in sickle cells in a hypoxic state
Data Source
AI summary
An agent for ameliorating and/or preventing sickle cell disease, includes 5-aminolevulinic acid (ALA) or a derivative thereof or a salt thereof. The agent is useful for amelioration and/or prevention of sickle cell disease. The agent may include one or more kinds of metal-including compounds. The metal in the metal-including compound can be any of several different metals, including iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum, or cobalt.